# EDGAR Filing Document

**Accession Number:** 0001827506
**File Stem:** 0001104659-25-100641
**Filing Date:** 2025-10
**Character Count:** 7500
**Document Hash:** d7913239f137b303a41afd1843719e97
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-100641.hdr.sgml**: 20251020

**ACCESSION NUMBER**: 0001104659-25-100641

**CONFORMED SUBMISSION TYPE**: SC TO-T/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251020

**DATE AS OF CHANGE**: 20251020

**GROUP MEMBERS**: TORINO MERGER SUB INC.

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tourmaline Bio, Inc.
- **CENTRAL INDEX KEY:** 0001827506
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92543
- **FILM NUMBER:** 251402402

**BUSINESS ADDRESS:**
- **STREET 1:** 27 WEST 24TH STREET
- **STREET 2:** SUITE 702
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** 646-481-9832

**MAIL ADDRESS:**
- **STREET 1:** 27 WEST 24TH STREET
- **STREET 2:** SUITE 702
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Talaris Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20201007
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NOVARTIS AG
- **CENTRAL INDEX KEY:** 0001114448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-T/A

**BUSINESS ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** CH 4056
- **BUSINESS PHONE:** 01141613241111

**MAIL ADDRESS:**
- **STREET 1:** LICHTSTRASSE 35
- **CITY:** BASEL
- **STATE:** V8
- **ZIP:** CH 4056

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE TO**

**TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR (13)(E)(1) <br> OF THE SECURITIES EXCHANGE ACT OF 1934**

**(Amendment No. 1)**

**TOURMALINE BIO, INC.**

(Name of Subject Company (Issuer))

**TORINO MERGER SUB INC.**

(Offeror)<br> an indirect wholly owned subsidiary of

**NOVARTIS AG**

(Offeror)<br> (Name of Filing Persons (identifying status as offeror, issuer or other person))

**Common Stock, par value $0.0001 per share**

(Title of Class of Securities)

**89157D105**

(CUSIP Number of Class of Securities)

**Karen L. Hale<br> Chief Legal and Compliance Officer<br> Novartis AG<br> Lichstrasse 35<br> CH-4056 Basel<br> Switzerland<br> Telephone: +41-61-324-1111**

(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

**With copies to:**

**Joseph E. Gilligan**

**Mahvesh A. Qureshi**

**Gabrielle M. Witt**

**Jessica A. Bisignano<br> Hogan Lovells US LLP<br> 555 Thirteenth Street, NW<br> Washington, DC 20004-1109<br> +1 (202) 637-5600**

◻ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

⌧ Third-party tender offer subject to Rule 14d-1.

◻ Issuer tender offer subject to Rule 13e-4.

◻ Going-private transaction subject to Rule 13e-3.

◻ Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ◻

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

◻ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

◻ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This Amendment No. 1 to the Tender Offer Statement on Schedule TO (this "**Amendment**") amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on September 29, 2025 (as it may be amended and supplemented from time to time, the "**Schedule TO**") by (i) Torino Merger Sub Inc., a Delaware corporation ("**Purchaser**") and an indirect wholly owned subsidiary of Novartis AG, a company limited by shares (*Aktiengesellschaft*) incorporated under the laws of Switzerland ("**Parent**"), and (ii) Parent. The Schedule TO relates to the offer by Purchaser (the "**Offer**") to purchase all of the outstanding shares of common stock, par value $0.0001 per share (the "**Shares**"), of Tourmaline Bio, Inc., a Delaware corporation, at a price of $48.00 per Share, in cash, without interest and subject to any withholding of taxes required by applicable legal requirements. The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated September 29, 2025, and in the related Letter of Transmittal, copies of which are attached as Exhibits (a)(1)(A) and (a)(1)(B) to the Schedule TO, respectively.

This Amendment is being filed solely to amend and supplement items to the extent specifically provided herein. Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO, including all exhibits thereto, remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. This Amendment should be read together with the Schedule TO. Capitalized terms used but not defined herein have the meanings ascribed to them in the Schedule TO, as amended by this Amendment.

***Items 1 through 9 and Item 11***.

Items 1 through 9 and Item 11 of the Schedule TO are hereby amended and supplemented as follows:

The information set forth in "Section 16—*Certain Legal Matters; Regulatory Approvals*" of the Offer to Purchase is hereby amended and supplemented by adding at the end of the section a subsection titled "*Litigation*" and the following paragraph:

"Lawsuits were filed by purported stockholders of the Company in connection with the transactions contemplated by the Merger Agreement in the Supreme Court of the State of New York on October 7, 2025 and October 9, 2025 under the captions *Kevin Welsh v. Tourmaline Bio, Inc. et al.*, Case No. 655975/2025 and *William Ballard v. Tourmaline Bio, Inc. et al.*, Case No. 656012/2025 asserting claims for negligent misrepresentation and concealment against the Company and the Company Board based on allegedly false and misleading statements in the Schedule 14D-9. In addition, the Company received fourteen demand letters from purported stockholders relating to alleged disclosure deficiencies in the Schedule 14D-9. If additional, similar demands or complaints are received by or filed against Parent or Purchaser, absent new or different allegations that are material, Parent and Purchaser will not necessarily announce such occurrences."

**SIGNATURES**

After due inquiry and to the best knowledge and belief of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

---

| | |
|:---|:---|
| **Torino Merger Sub Inc.** | **Torino Merger Sub Inc.** |
| By: | /s/ Jaime Huertas |
| Name: Jaime Huertas | Name: Jaime Huertas |
| Title: Secretary | Title: Secretary |
| **Novartis AG** | **Novartis AG** |
| By: | /s/ Jonathan Emery |
| Name: Jonathan Emery | Name: Jonathan Emery |
| Title: Attorney-in-fact | Title: Attorney-in-fact |
| By: | /s/ Ram Narayan |
| Name: Ram Narayan | Name: Ram Narayan |
| Title: Attorney-in-fact | Title: Attorney-in-fact |
| Date: October 20, 2025 | Date: October 20, 2025 |

---